ETF Holdings Breakdown of RCKT

News associated with RCKT

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives $18.60 Consensus Target Price from Analysts

Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) have been given a consensus recommendation of “Hold” by the seventeen analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the […] - 2025-06-25 06:02:58

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Rating Lowered by The Goldman Sachs Group

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) was downgraded by analysts at The Goldman Sachs Group from a “neutral” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Marketbeat reports. A number of other research firms have also recently weighed in on RCKT. JPMorgan Chase & Co. cut […] - 2025-05-30 07:34:55

Chardan Capital Lowers Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $17.00

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) had its price target reduced by research analysts at Chardan Capital from $46.00 to $17.00 in a report released on Wednesday, MarketBeat.com reports. The firm presently has a “buy” rating on the biotechnology company’s stock. RCKT has been the topic of several other research reports. Jefferies Financial Group […] - 2025-05-30 07:34:54

Morgan Stanley Reiterates Equal Weight Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report)‘s stock had its “equal weight” rating restated by equities researchers at Morgan Stanley in a note issued to investors on Wednesday, MarketBeat Ratings reports. They currently have a $7.00 target price on the biotechnology company’s stock. Morgan Stanley’s target price suggests a potential upside of 167.18% from the […] - 2025-05-30 07:34:51

Jefferies Financial Group Reiterates “Hold” Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report)‘s stock had its “hold” rating reiterated by equities research analysts at Jefferies Financial Group in a research report issued to clients and investors on Wednesday, Marketbeat.com reports. Other equities research analysts have also recently issued research reports about the company. JPMorgan Chase & Co. cut their target price […] - 2025-05-30 05:16:46

Rocket Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RCKT)

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) saw unusually large options trading on Tuesday. Traders acquired 2,414 call options on the company. This is an increase of 426% compared to the typical volume of 459 call options. Rocket Pharmaceuticals Stock Performance RCKT opened at $2.48 on Thursday. The stock’s 50 day simple moving average […] - 2025-05-29 08:14:57

BMO Capital Markets Issues Pessimistic Forecast for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price

Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its price target trimmed by BMO Capital Markets from $30.00 to $8.00 in a research report sent to investors on Wednesday,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock. Several other equities analysts also recently commented on the stock. Cantor Fitzgerald upped their […] - 2025-05-29 07:40:53

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 3,985 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 2.3% in the 4th quarter, HoldingsChannel reports. The fund owned 177,548 shares of the biotechnology company’s stock after buying an additional 3,985 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Rocket Pharmaceuticals were […] - 2025-05-22 08:51:02

Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Raised to $30.00

Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its price target increased by Cantor Fitzgerald from $20.00 to $30.00 in a research report sent to investors on Friday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for Rocket Pharmaceuticals’ FY2025 earnings at ($2.28) EPS. RCKT has […] - 2025-05-19 06:12:47

Voya Investment Management LLC Sells 1,493 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Voya Investment Management LLC trimmed its stake in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 7.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,975 shares of the biotechnology company’s stock after selling 1,493 shares […] - 2025-05-13 08:20:49

Canaccord Genuity Group Has Lowered Expectations for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price

Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its target price cut by Canaccord Genuity Group from $36.00 to $34.00 in a research report report published on Monday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. A number of other equities analysts have also issued reports on the stock. Scotiabank raised their […] - 2025-05-13 05:56:45

Raymond James Financial Inc. Makes New $285,000 Investment in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Raymond James Financial Inc. acquired a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) during the 4th quarter, HoldingsChannel.com reports. The firm acquired 22,645 shares of the biotechnology company’s stock, valued at approximately $285,000. Several other large investors have also recently bought and sold shares of the company. SG Americas Securities […] - 2025-05-12 07:20:58

Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $45.00 at Chardan Capital

Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its price objective decreased by Chardan Capital from $54.00 to $45.00 in a research note issued to investors on Friday,Benzinga reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock. Several other equities analysts also recently commented on the company. BMO Capital Markets assumed coverage […] - 2025-05-12 05:38:47

Mariner LLC Takes Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Mariner LLC bought a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,061 shares of the biotechnology company’s stock, valued at approximately $139,000. Other institutional investors […] - 2025-05-09 07:36:56

Analysts Set Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) PT at $43.00

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) has earned a consensus rating of “Moderate Buy” from the twelve research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 1 […] - 2025-05-06 06:07:08

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Bought by Legal & General Group Plc

Legal & General Group Plc raised its holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 3.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 75,454 shares of the biotechnology company’s stock after purchasing an additional 2,416 shares during the quarter. […] - 2025-04-28 07:56:54

Raymond James Financial Inc. Acquires Shares of 22,645 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Raymond James Financial Inc. acquired a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 22,645 shares of the biotechnology company’s stock, valued at approximately $285,000. Other hedge funds and other institutional investors have also made changes to their positions in the […] - 2025-04-11 07:56:49

Mitsubishi UFJ Asset Management Co. Ltd. Has $254,000 Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 68.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,196 shares of the biotechnology company’s stock after buying an additional 8,190 […] - 2025-04-04 08:12:55

Blair William & Co. IL Reduces Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Blair William & Co. IL reduced its stake in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 14.0% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 116,038 shares of the biotechnology company’s stock after selling 18,931 shares during the quarter. Blair William & Co. IL’s holdings in Rocket Pharmaceuticals were worth […] - 2025-04-03 08:27:07

Teacher Retirement System of Texas Purchases 7,211 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Teacher Retirement System of Texas raised its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 45.2% during the 4th quarter, Holdings Channel reports. The fund owned 23,148 shares of the biotechnology company’s stock after purchasing an additional 7,211 shares during the period. Teacher Retirement System of Texas’ holdings in Rocket Pharmaceuticals […] - 2025-04-02 07:42:48

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Bought by Signaturefd LLC

Signaturefd LLC grew its holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 319.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,916 shares of the biotechnology company’s stock after buying an additional 3,745 shares during the quarter. Signaturefd LLC’s holdings […] - 2025-03-25 08:03:00

Harbour Investments Inc. Acquires 1,840 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Harbour Investments Inc. lifted its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 51.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 5,385 shares of the biotechnology company’s stock after acquiring an additional 1,840 shares during the period. Harbour Investments Inc.’s holdings in Rocket Pharmaceuticals were worth $68,000 as of […] - 2025-03-24 08:02:55

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) have been given an average rating of “Moderate Buy” by the twelve analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. The […] - 2025-03-14 07:12:56

Canaccord Genuity Group Has Lowered Expectations for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) had its price target lowered by research analysts at Canaccord Genuity Group from $39.00 to $36.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 315.70% […] - 2025-03-05 10:08:58

Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 1-Year Low on Analyst Downgrade

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) shares reached a new 52-week low on Monday after The Goldman Sachs Group lowered their price target on the stock from $29.00 to $15.00. The Goldman Sachs Group currently has a neutral rating on the stock. Rocket Pharmaceuticals traded as low as $8.93 and last traded at […] - 2025-03-04 06:56:43

Rocket Pharmaceuticals (NASDAQ:RCKT) Given New $54.00 Price Target at Chardan Capital

Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its target price decreased by Chardan Capital from $62.00 to $54.00 in a research report report published on Friday morning,Benzinga reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock. Other research analysts have also issued reports about the stock. Cantor Fitzgerald reissued an “overweight” […] - 2025-03-03 06:48:48

Strategic Financial Concepts LLC Makes New Investment in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Strategic Financial Concepts LLC bought a new stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) in the 4th quarter, Holdings Channel.com reports. The fund bought 11,250 shares of the biotechnology company’s stock, valued at approximately $141,000. A number of other institutional investors and hedge funds also recently made changes to their positions in the […] - 2025-02-13 09:05:07

Jennison Associates LLC Raises Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Jennison Associates LLC lifted its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 72.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,304 shares of the biotechnology company’s stock after acquiring an additional 29,564 shares during the quarter. […] - 2025-02-07 09:59:00

RCKT institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	53,155	USD 137,671
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	150,290	USD 389,251
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	50,836	USD 131,665
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	50,836	USD 131,665
2025-06-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	6,474	USD 16,768
Total =		311,591	USD 807,020

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer